This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

The transition from preclinical development to clinical trials is a critical, with approximately 89% of drugs failing. Nearly half of these failures stem from unexpected and unmanageable human ...

Sustainability-by-design in bioprocess development, according to Adam Goldstein, senior director of R&D Collaborations at ...

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb ...

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A research team has pioneered a groundbreaking method that could accelerate drug discovery and reduce pharmaceutical development costs. Their work introduces a safe, sustainable way to insert a single ...

In the pivotal, Phase III NUC-5 trial, (NCT03872921), NCA showed statistical superiority over placebo in achieving the ...